Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation
Authors:
- 1 October 2009
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 29 (10) , 655-665
Abstract
Background and Objective: Varenicline is a nicotinic acetylcholine receptor partial agonist that is approved for use as an aid to smoking cessation. Randomized clinical trials show that its efficacy is superior to that of other current smoking cessation therapies. This study set out to determine the cost effectiveness of varenicline relative to other smoking cessation interventions (bupropion and nicotine replacement therapy [NRT]) as well as brief counselling alone and unaided cessation in a cohort of Belgian adult smokers making a one-time quit attempt, from the perspective of the healthcare payer (public and private). Methods: A Markov model, the Benefits of Smoking Cessation on Outcomes (BENESCO) model, was applied to calculate the long-term health and economic benefits of smoking cessation. Cost effectiveness was expressed as cost per life-year (LY) gained and cost per quality-adjusted life-year (QALY) gained. Clinical and economic model inputs were obtained from the literature and public healthcare databases. Costs were discounted at 3% and health outcomes at 1.5%. A probabilistic sensitivity analysis and a one-way sensitivity analysis were performed to test the robustness of the results. Results: Varenicline is associated with a reduction of smoking-related morbidity and mortality as well as with a decrease in healthcare costs compared with the pharmacological agents bupropion and NRT. Varenicline also leads to additional LYs and QALYs compared with brief counselling alone and unaided cessation over a lifetime period. Varenicline is a dominant strategy compared with bupropion and NRT. Compared with brief counselling alone and unaided cessation, varenicline presents a cost/QALY of €240 and €1656, respectively. Conclusion: Varenicline is a cost-effective alternative to brief counselling and unaided cessation, and is a cost-saving treatment in comparison with bupropion and NRT, in a Belgian population of smokers willing to quit.Keywords
This publication has 28 references indexed in Scilit:
- Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation ModelPharmacoEconomics, 2008
- An Employer-Based Cost-Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking CessationJournal of Occupational and Environmental Medicine, 2007
- Nicotine receptor partial agonists for smoking cessation2007
- Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling StudyValue in Health, 2005
- Late relapse/sustained abstinence among former smokers: a longitudinal studyPreventive Medicine, 2004
- Advances in pharmacotherapy for tobacco dependenceExpert Opinion on Emerging Drugs, 2004
- Psychometric and Utility-Based Measures of Health Status of Asthmatic Patients with Different Disease Control LevelPharmacoEconomics, 2004
- Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging StudyNicotine & Tobacco Research, 2002
- Quality of Life and Utility in Patients with Non-Small Cell Lung CancerPharmacoEconomics, 2001
- Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches.BMJ, 1993